Roche says Ocrevus drug reduces need for walking aids for MS patients

ZURICH, Oct 13 (Reuters) – Roche (ROG.S) said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday.

A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012. REUTERS/Michael Buholzer/File Photo

There was a 35% reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29% reduction in the 48-week progression in primary progressive MS after 8 years after starting taking the drug, it added.

Reporting by John Revill; Editing by Kim Coghill

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: